International, multi-center, open-label 9-month FOLLOW-UP extension study assessing the long term safety and tolerability of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.

Trial Profile

International, multi-center, open-label 9-month FOLLOW-UP extension study assessing the long term safety and tolerability of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Baclofen/naltrexone/sorbitol (Primary)
  • Indications Charcot-Marie-Tooth disease
  • Focus Adverse reactions
  • Acronyms PLEO-CMT-FU
  • Sponsors Pharnext
  • Most Recent Events

    • 28 Oct 2017 Study design has been changed from double blind to open label.
    • 18 Sep 2017 According to a Pharnext media release, the data from PLEO-CMT trial will form the basis of the submission package for market approval in the first quarter of 2019. Long-term safety data from PLEO-CMT-FU would then be submitted to regulatory authorities during their review of the marketing authorization application.
    • 18 Sep 2017 According to a Pharnext media release, the company has decided to switch high dose patients patients to receive double the amount of dose 1 (2 x 5 mL) in the 9-month open label extension study (PLEO-CMT-FU). Patients from the placebo and dose 1 arms in the 15-month double blind PLEO-CMT study will continue the Phase 3 clinical trial as planned: then, these patients will have the opportunity to continue treatment with PXT3003 in the PLEO-CMT-FU extension study for 9 months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top